Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial
Articles > Article · 2018
Authors: G.D. Goss, M. Cobo, S. Lu, K. Syrigos, K.H. Lee, Erdem GÖKER, V. Georgoulias, W. Li, D. Isla, A. Morabito, Y.J. Min, A. Ardizzoni, A. Cseh, S. Bender, E. Felip
Annals of Oncology, International, WoS, 2018, vol 29, pp viii521-viii521
DOI: 10.1093/annonc/mdy292.064
Summary
Background: Primary LL8 data showed significantly improved PFS and OS with afatinib compared with erlotinib as second-line treatment in pts with lung SCC, leading to the approval of afatinib in this setting. As previously reported (data cut-off: Apr 2015), PFS (2.6 vs 1.9 months; HR 0.81 [95% CI 0.69–0.96]; p=0.01), objective response rate (ORR; 5.5 vs 2.8%; p=0.06) and disease control rate (DCR; 50.5 vs 39.5%; p=0.002) were higher with afatinib vs erlotinib. PFS and OS benefits on afatinib appeared even greater for pts with ErbB mutation-positive tumours vs ErbB wild-type tumours.